Lucid Capital Markets Starts Avalo Therapeutics Inc. (AVTX) at Buy
Tweet
Share
E-mailGet Alerts AVTX Hot Sheet
Price: $19.45 --0%
Rating Summary:
16 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 8
Rating Summary:
16 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 8
Join SI Premium – FREE
Lucid Capital Markets analyst Dev Prasad initiates coverage on Avalo Therapeutics Inc. (NASDAQ: AVTX) with a Buy rating and a price target of $24.00.
For an analyst ratings summary and ratings history on Avalo Therapeutics Inc. click here. For more ratings news on Avalo Therapeutics Inc. click here.
Shares of Avalo Therapeutics Inc. closed at $9.42 yesterday.
You May Also Be Interested In
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
- JPMorgan Starts Neway Valve Suzhou Co Ltd (603699:CH) at Overweight
- Alliance Global Partners Starts Momentus (MNTS) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
